# Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

> **NCT02310581** · PHASE3 · TERMINATED · sponsor: **INSYS Therapeutics Inc** · enrollment: 40 (actual)

## Conditions studied

- Post-operative Pain

## Interventions

- **DRUG:** Buprenorphine Sublingual Spray
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02310581
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-24
- **Primary completion:** 2015-03-19
- **Final completion:** 2015-03-19
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2017-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02310581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02310581, "Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02310581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*